Janus Henderson Global Life Sciences Fund Class I (JFNIX)

Fund Assets	5.80B
Expense Ratio	0.78%
Min. Investment	$1,000,000
Turnover	30.00%
Dividend (ttm)	0.38
Dividend Yield	0.44%
Dividend Growth	32.87%
Payout Frequency	Annual
Ex-Dividend Date	Dec 5, 2025

Previous Close	86.91
YTD Return	5.73%
1-Year Return	20.97%
5-Year Return	46.66%
52-Week Low	73.99
52-Week High	94.43
Beta (5Y)	0.79
Holdings	98
Inception Date	Jul 6, 2009

About JFNIX

Janus Henderson Global Life Sciences Fund Class I is an open-end mutual fund specializing in global equities within the life sciences sector. Its primary objective is to achieve long-term capital growth by investing at least 80% of its assets in companies with a life sciences orientation, spanning industries such as biotechnology, pharmaceuticals, medical devices, and health care services. The fund pursues a diversified, actively managed approach, allocating assets across various market capitalizations and geographies, including up to 20% in developing markets. With a focus on addressing unmet medical needs and enhancing health care system efficiency, portfolio holdings typically include prominent global health care companies. The fund’s management team employs rigorous fundamental research and risk management processes to construct a balanced portfolio. It benchmarks its performance mainly against the MSCI World Health Care Index, aiming to outperform the index by 2% per annum over a rolling five-year period. The fund is designed for institutional investors, offering a competitive expense ratio and leveraging the expertise of a specialized investment team with deep domain knowledge in health care innovation.

• Fund Family: Janus Henderson
• Category: Health
• Performance Rating: High
• Risk Rating: Average
• Stock Exchange: Nasdaq
• Ticker Symbol: JFNIX
• Share Class: Class I
• Index: MSCI World/Health Care NR

Performance

JFNIX had a total return of 20.97% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.95%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.68%
JNGLX	Class D	0.81%
JAGLX	Class T	0.92%
JFNAX	Class A	1.00%

Top 10 Holdings

42.22% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	9.05%
Johnson & Johnson	JNJ	7.48%
AbbVie Inc.	ABBV	4.63%
UnitedHealth Group Incorporated	UNH	4.33%
AstraZeneca PLC	AZN	3.50%
Thermo Fisher Scientific Inc.	TMO	2.92%
Novartis AG ADR	NVSN.MX	2.78%
Roche Holding AG	ROP	2.63%
argenx SE	ARGX	2.55%
Abbott Laboratories	ABT	2.36%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 5, 2025	$3.71003	Dec 5, 2025
Dec 6, 2024	$3.99969	Dec 6, 2024
Dec 7, 2023	$2.96525	Dec 7, 2023
Dec 20, 2022	$0.20212	Dec 20, 2022
Dec 20, 2021	$6.8555	Dec 20, 2021
Dec 17, 2020	$5.6057	Dec 17, 2020

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 9, 2026

Data Sources Report a data error